Group 1 - The core focus of Inventiva is the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) [4] - Inventiva will participate in two investor conferences in June 2025, including the Jefferies Global Healthcare Conference and the UBS Spring Biotech Conference [2][3] - Frédéric Cren, CEO of Inventiva, will present a corporate overview during a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025 [2] Group 2 - Inventiva is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for MASH treatment [4] - The company is publicly listed on Euronext Paris and NASDAQ, with the ticker symbol IVA [5]